Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz
Johnson & Johnson (NYSE:JNJ) is reportedly readying an investor roadshow to pitch shares of its consumer-healthcare spinoff business, dubbed Kenvue,…